Literature DB >> 7522312

Epidemiologic predictors of hepatitis C virus infection in pregnant women.

E L Leikin1, J F Reinus, E Schmell, N Tejani.   

Abstract

OBJECTIVE: To identify sensitive epidemiologic predictors of a positive hepatitis C virus antibody test in asymptomatic persons, and to compare the cost of testing only persons with an epidemiologic predictor to that of universal screening.
METHODS: Seventeen hundred consecutive pregnant women were tested by enzyme-linked immunosorbent assay for antibody to hepatitis C virus. Seventy-five subjects tested positive and were compared with 257 pregnant women who tested negative. Cohort and control patients were interviewed and their medical records were reviewed to identify those with chosen predictors of a positive hepatitis C virus antibody test.
RESULTS: Seventy-four of 75 cohort patients and 108 of 257 controls had one or more predictors of a positive antibody test. Cohort patients were significantly more likely (P < .001) to have the following: human immunodeficiency virus infection, a sex partner with a risk factor for hepatitis, age greater than 30 years, and a history of drug use, blood transfusion, sexually transmitted disease, hepatitis, or incarceration. The sensitivity and specificity of a single predictor in identifying a person with a positive test were 99 and 58%, respectively. The cost of finding a single individual with a positive antibody test by universal screening was $674, compared to $303 by selectively screening persons with one or more predictors of a positive antibody test.
CONCLUSIONS: Most individuals with positive hepatitis C virus antibody tests can be identified on the basis of epidemiologic predictors, reducing the cost of testing by 55%. These patients may receive appropriate medical therapy, and their children may be evaluated for possible infection by vertical transmission of hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522312

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Hepatitis C infection among pregnant women in British Columbia: reported prevalence and critical appraisal of current prenatal screening methods.

Authors:  Audrey Blasig; Emily C Wagner; David Pi; Mark Bigham; Valencia P Remple; Kevin J P Craib; Patrick Doyle; Simon Dobson; Eric M Yoshida; David Patrick; Mel Krajden; Deborah M Money
Journal:  Can J Public Health       Date:  2011 Mar-Apr

2.  Viral invasion of the amniotic cavity (VIAC) in the midtrimester of pregnancy.

Authors:  Maria-Teresa Gervasi; Roberto Romero; Gabriella Bracalente; Tinnakorn Chaiworapongsa; Offer Erez; Zhong Dong; Sonia S Hassan; Lami Yeo; Bo Hyun Yoon; Gil Mor; Luisa Barzon; Elisa Franchin; Valentina Militello; Giorgio Palù
Journal:  J Matern Fetal Neonatal Med       Date:  2012-05-30

3.  Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort.

Authors:  Steven A Pergam; Chia C Wang; Carolyn M Gardella; Taylor G Sandison; Warren T Phipps; Stephen E Hawes
Journal:  Am J Obstet Gynecol       Date:  2008-05-19       Impact factor: 8.661

4.  Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis.

Authors:  S J Hutchinson; D J Goldberg; M King; S O Cameron; L E Shaw; A Brown; J MacKenzie; K Wilson; L MacDonald
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 5.  Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.

Authors:  Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

6.  Risk factors for hepatitis C infection among sexually transmitted disease-infected, inner city obstetric patients.

Authors:  Youyin Choy; Lisa Gittens-Williams; Joseph Apuzzio; Joan Skurnick; Carl Zollicoffer; Peter G McGovern
Journal:  Infect Dis Obstet Gynecol       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.